Haemonetics Corporation
HAENYSEHealthcareMedical Devices
As of Oct 16, 2026 close
- Market cap
- $5.54B
- P/E (TTM)
- 57.57
- Forward P/E
- 99.67
- Dividend yield
- -
- 52-week range
- $48.55$123.77
- Volume (live)
- -
- Avg. volume (3M)
- 671.54K
Haemonetics (HAE) Stock Price & Financial Analysis
Haemonetics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $118.19 - $121.84 |
|---|---|
| 52-Week High | $123.77 |
| 52-Week Low | $48.55 |
| Open | $121.83 |
| Volume (last close) | 467.01K |
| Average Volume (3M) | 671.54K |
| Revenue (TTM) | 1.35B |
|---|---|
| Net Income (TTM) | 96.29M |
| Free Cash Flow (TTM) | 291.22M |
| EPS (TTM) | $2.06 |
| Profit Margin | 7.12% |
| Operating Margin | 18.18% |
| Return on Equity (ROE) | 11.50% |
| Debt to Equity | 1.40 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 5.54B |
|---|---|
| Shares Outstanding | 45.70M |
| P/E Ratio (TTM) | 57.57 |
| Forward P/E | 99.67 |
| Price to Sales (P/S) | 4.10 |
| Price to Book (P/B) | 6.62 |
| EV/EBITDA | 23.96 |
| 50-Day MA | $103.76 |
|---|---|
| 200-Day MA | $76.38 |
| 1-Year Change | +141.33% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Haemonetics at a Glance
As of the Oct 16, 2026 close, Haemonetics (HAE) has a market capitalization of $5.54B. The stock trades at 57.6× trailing earnings, 99.7× forward earnings and 4.1× sales. Over the trailing twelve months it earned $96.29M on revenue of $1.35B (a 7.1% profit margin) and generated $291.22M of free cash flow. Revenue grew 0.4% year over year.
As of its latest reported balance sheet, it holds $223.38M in cash and securities against $1.17B of debt, a net debt position of $950.77M.
Haemonetics does not currently pay a dividend.
The share price is up 141.3% over the past year. At $118.28 (the Oct 16, 2026 close) it sits near the top of its 52-week range of $48.55 to $123.77, above its 200-day moving average of $76.38.
Based on 10 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $125.38, 6.0% above the Oct 16, 2026 close.
Frequently Asked Questions About Haemonetics
What is the current stock price for HAE?
As of the Oct 16, 2026 close, HAE stock trades at $118.28. The 52-week range is $48.55–$123.77, with a day range of $118.19–$121.84.
What is the P/E ratio for HAE?
As of the Oct 16, 2026 close, Haemonetics's trailing twelve-month (TTM) P/E ratio is 57.6, meaning investors pay $57.6 for every $1 of annual earnings. The forward P/E is 99.7, reflecting analyst expectations for future earnings. Haemonetics operates in the Healthcare sector.
Does HAE pay dividends?
Haemonetics does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for HAE?
Based on ratings from 10 professional analysts over the last 90 days, the consensus for HAE is Buy. The average 12-month price target is $125.38, a 6.0% upside from the Oct 16, 2026 close of $118.28.
What is the market cap of HAE?
As of the Oct 16, 2026 close, Haemonetics's market capitalization is $5.41B, classifying it as a mid-cap company. Haemonetics operates in the Healthcare sector within the Medical Devices industry.